StemCell Therapy

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systmes company, the global leader in creating end-to-end solutions that support the entire clinical trial process, will convene stakeholders in drug and device development, clinical operations, data management, biostatistics and digital medicine innovation industries for NEXT Global on October 27-29, 2020.

With a focus on improving clinical trials through advanced technology and enhancing the patient experience, the three-day, all virtual event will bring together experts to discuss topics critical to pharmaceutical and biotechnology companies, medical device and diagnostics companies, and contract research organizations (CROs) running clinical trials during the COVID-19 pandemic.

The COVID-19 pandemic is reshaping the life sciences industry and is acting as a catalyst for dramatic change, said Tarek Sherif, co-founder and co-CEO of Medidata. Digital transformation of life sciences is happening at an accelerated pace, from research to clinical trials, manufacturing and through to commercialization. Nowhere is this more apparent than in clinical studies, where the use of advanced analytics is powering faster, safer and more effective treatments. Medidatas platform is at the forefront of enabling clinical development to improve the patient experience and patient outcomes.

To see and hear how Medidatas industry-leading Rave platform and its innovative patient-centric approach is at the core of digitally transforming clinical trials, attendees will participate in sessions with the following themes:

Presentations from Medidata experts, customers, partners and industry experts will focus on the next phase of digital transformation in clinical trials and drug development through:

The right unified technology can embrace the waves of change and increase precision in medical therapies and treatments, said Glen de Vries, co-CEO of Medidata. NEXT Global will showcase technology solutions that accelerate clinical development, powering smarter treatments and healthier people.

Medidata is a wholly owned subsidiary of Dassault Systmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at http://www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systmes.

About Dassault Systmes

Dassault Systmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit http://www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systmes, a French socit europenne (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Read more here:
Medidata NEXT Global 2020 to Focus on the Virtualization of Clinical Trials, the Power of Analytics and Improving the Patient Experience in the...

This entry was posted on October 29, 2020 at 10:57 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |